{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:52:26Z","timestamp":1790790746970,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.clinbiochem.2025.111008","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:27:15Z","timestamp":1756945635000},"page":"111008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Clinical implementation and outcome evaluation of dihydropyrimidine dehydrogenase (DPYD) pharmacogenomic testing for fluoropyrimidine dosing in a Canadian Provincial Healthcare center"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1225-5062","authenticated-orcid":false,"given":"Fang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Abdelfatah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayananda","family":"Kundapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergall","family":"Magee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2025.111008_b0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ctrv.2016.08.002","article-title":"Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - ready for clinical practice?","volume":"50","author":"Meulendijks","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"12","key":"10.1016\/j.clinbiochem.2025.111008_b0010","first-page":"4705","article-title":"Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene","volume":"6","author":"van Kuilenburg","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.clinbiochem.2025.111008_b0015","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.1998.16.11.3537","article-title":"Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors","volume":"16","author":"Levy","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.clinbiochem.2025.111008_b0020","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.clinbiochem.2025.111008_b0025","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.111008_b0030","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1517\/14740338.2010.511610","article-title":"Safety of capecitabine: a review","volume":"9","author":"Mikhail","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.clinbiochem.2025.111008_b0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0065-2571(00)00011-X","article-title":"Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil","volume":"41","author":"Johnson","year":"2001","journal-title":"Adv. Enzyme Regul."},{"issue":"11","key":"10.1016\/j.clinbiochem.2025.111008_b0040","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2217\/pgs.15.70","article-title":"Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score","volume":"16","author":"Henricks","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clinbiochem.2025.111008_b0045","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/1471-2407-8-188","article-title":"Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy","volume":"8","author":"Ishikawa","year":"2008","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.clinbiochem.2025.111008_b0050","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju298","article-title":"DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)","volume":"106","author":"Lee","year":"2014","journal-title":"J. Natl Cancer Inst."},{"issue":"5","key":"10.1016\/j.clinbiochem.2025.111008_b0055","first-page":"1149","article-title":"Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency","volume":"7","author":"van Kuilenburg","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.111008_b0060","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.clinbiochem.2025.111008_b0065","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jmoldx.2024.05.015","volume":"26","author":"Pratt","year":"2024","journal-title":"J. Mol. Diagn."},{"issue":"8","key":"10.1016\/j.clinbiochem.2025.111008_b0070","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/FPC.0000000000000505","article-title":"Implementation of upfront DPYD genotyping with a low-cost and high-throughput assay to guide fluoropyrimidine treatment in cancer patients","volume":"33","author":"Pinheiro","year":"2023","journal-title":"Pharmacogenet. Genomics"},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111008_b0075","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","article-title":"Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines","volume":"28","author":"Lunenburg","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111008_b0080","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","article-title":"Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis","volume":"34","author":"Deenen","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111008_b0085","doi-asserted-by":"crossref","DOI":"10.1177\/1559325818803042","article-title":"Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase deficiency in patients with colorectal cancer: a single-institution experience","volume":"16","author":"Murphy","year":"2018","journal-title":"Dose Response"},{"key":"10.1016\/j.clinbiochem.2025.111008_b0090","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2018.11.010","article-title":"A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy","volume":"107","author":"Henricks","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111008_b0095","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cpt.1257","article-title":"The genotype for DPYD Risk variants in patients with colorectal cancer and the related toxicity management costs in clinical practice","volume":"105","author":"Toffoli","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.111008_b0100","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.ajhg.2019.04.017","article-title":"Estimating the effectiveness of DPYD genotyping in Italian individuals suffering from cancer based on the cost of chemotherapy-induced toxicity","volume":"104","author":"Fragoulakis","year":"2019","journal-title":"Am. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.111008_b0105","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/curroncol29020045","article-title":"Upfront DPYD genotyping and toxicity associated with fluoropyrimidine-based concurrent chemoradiotherapy for oropharyngeal carcinomas: a work in progress","volume":"29","author":"Desilets","year":"2022","journal-title":"Curr. Oncol."},{"issue":"6","key":"10.1016\/j.clinbiochem.2025.111008_b0110","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2217\/pgs.09.28","article-title":"Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment","volume":"10","author":"Amstutz","year":"2009","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111008_b0115","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.gim.2021.12.009","article-title":"Clinical pharmacogenomic testing and reporting: a technical standard of the American College of Medical Genetics and Genomics (ACMG)","volume":"24","author":"Tayeh","year":"2022","journal-title":"Genet. Med."},{"issue":"8","key":"10.1016\/j.clinbiochem.2025.111008_b0120","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41416-019-0423-8","article-title":"The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian Case-Control Study","volume":"120","author":"Iachetta","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.clinbiochem.2025.111008_b0125","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13699","article-title":"Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing","volume":"17","author":"Turner","year":"2024","journal-title":"Clin. Transl. Sci."},{"issue":"9","key":"10.1016\/j.clinbiochem.2025.111008_b0130","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/ijc.32022","article-title":"Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: a matched pair analysis","volume":"144","author":"Henricks","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.clinbiochem.2025.111008_b0135","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10549-019-05144-9","article-title":"Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients","volume":"175","author":"Stavraka","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.clinbiochem.2025.111008_b0140","doi-asserted-by":"crossref","first-page":"e597","DOI":"10.1002\/onco.13626","article-title":"Implementing DPYD*2A genotyping in clinical practice: the Quebec, Canada, experience","volume":"26","author":"Jolivet","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.clinbiochem.2025.111008_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1257745","article-title":"Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2025.111008_b0150","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jmoldx.2021.11.008","article-title":"Targeted genotyping in clinical pharmacogenomics: What is missing?","volume":"24","author":"Lopes","year":"2022","journal-title":"J. Mol. Diagn."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912025001377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912025001377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T09:43:09Z","timestamp":1783158189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912025001377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"alternative-id":["S0009912025001377"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2025.111008","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical implementation and outcome evaluation of dihydropyrimidine dehydrogenase (DPYD) pharmacogenomic testing for fluoropyrimidine dosing in a Canadian Provincial Healthcare center","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2025.111008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The Canadian Society of Clinical Chemists.","name":"copyright","label":"Copyright"}],"article-number":"111008"}}